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IPM: Pioneering HIV
Prevention Options for Women

N

ineteen years ago, the International Partnership for Microbicides (IPM) entered the HIV prevention field with
a promise and a clear vision to create products that women in developing countries could use discreetly to

prevent HIV and protect their sexual and reproductive health. Every step we have taken since then has brought
that vision into sharper focus. Today, IPM is poised to introduce the first monthly HIV prevention product choice,
specifically designed for women.
The HIV/AIDS epidemic continues to disproportionately
affect women, especially in developing countries. Currently
available prevention options are often not practical for many
women, who urgently need new tools they can control and
that make sense for their lives. IPM’s monthly dapivirine
ring and other technologies in development could help
empower women with discreet and long-acting tools they
can use to protect their health, on their own terms.

Our Progress
Since IPM was founded as a nonprofit organization in 2002,
we have leveraged public, philanthropic and private
sector resources to accelerate the development of potentially
lifesaving technologies for women.
IPM builds on partnerships—with governments, foundations, researchers, pharmaceutical companies, policymakers, advocates and communities—to bring scientific
ingenuity, political will and financial resources to bear on all
phases of product development. Key achievements include:
n

Developing the first long-acting HIV prevention
product specifically for women

IPM led the development and testing of the monthly
dapivirine vaginal ring, designed to deliver the antiretroviral
(ARV) drug dapivirine over the course of one month.
Women can insert and remove the ring themselves.
By marshalling scientific know-how and resources through
partnerships, we took a novel approach to developing
woman-controlled HIV prevention technologies that have
significant public health potential but lack a traditional
market incentive.

IPM’s monthly dapivirine ring is currently under regulatory review.

countries. In 2021, the World Health Organization recommended the product in its updated clinical guidelines, an
important step that will inform country-level policymaking.
IPM is seeking country regulatory approvals for the ring’s
use in sub-Saharan Africa, where women have an urgent
unmet need for new prevention choices. The ring received
approval in Zimbabwe and several other countries in the
region in 2021, with additional reviews underway.
n

Negotiating innovative licenses for potent ARVs

Since our inception, IPM has negotiated royalty-free licenses and an exclusive worldwide rights agreement from five
leading pharmaceutical companies to develop nine promising ARVs as microbicides. These licenses ensure future IPM
products will be affordable where the need is most urgent.

Two Phase III trials found that the dapivirine ring reduced
women’s HIV risk with no safety concerns, and subsequent
open-label extension studies saw increased product use and
suggested greater risk reduction. In 2020, the dapivirine
ring received a positive regulatory opinion by the European
Medicines Agency for use by women in developing
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n

Conducting rigorous research studies

IPM has worked in 11 countries in Africa, Europe and
North America to conduct more than 35 clinical trials to
date on a variety of products as well as 13 incidence studies and two acceptability studies, all of which continue to
inform our work and the field.
n

n

Building on dapivirine ring research

In addition, IPM is leveraging its ring technology to develop
follow-on products that advance the science of HIV prevention, including a three-month dapivirine-only ring. The first
Phase I trial of the three-month dapivirine ring reported encouraging results in 2021, with plans for an additional study.

Strengthening medical research capacity

IPM has collaborated with in-country partners and research
staff to build and strengthen capacity at more than 15
research centers in sub-Saharan Africa. We trained more
than 600 research center clinical staff, including community
engagement teams, on microbicide trial implementation
and HIV and health literacy. These staff are equipped to
conduct rigorous HIV prevention and other clinical trials
that contribute to the health of their communities.
n

Streamlining manufacturing processes

IPM led a state-of-the-art manufacturing facility to produce
vaginal gel and ring prototypes for early trials, resolving a
manufacturing bottleneck and saving costs for more than
10 clinical studies. Because no manufacturers had previously produced vaginal rings for HIV prevention, IPM engineered the technology and manufacturing processes.
We later transferred ring production to a commercial
partner, Sever Pharma Solutions (formerly QPharma),
beginning with our Phase III studies to ensure cost-efficiencies for large-scale production. IPM has continued to work
with Sever Pharma Solutions to upgrade its manufacturing
capacity in preparation for the dapivirine ring’s potential
introduction, to keep production costs as low as possible.

What May the Future Hold?
n

Expanded HIV prevention choices for women

IPM is collaborating with global, regional and national
partners to determine how the dapivirine ring could fit into
combination prevention strategies, and to plan for its potential rollout, including supporting women to make informed
choices.

Realizing the lifesaving potential of
new products for women may be
within our reach.
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A research staff member demonstrates how to insert a vaginal ring at a
journalist training on women’s HIV prevention and microbicides.

Advancing multipurpose tools to meet women’s
overlapping sexual and reproductive health needs
n

Because HIV and unintended pregnancy are major
causes of serious health complications and death for women
worldwide, IPM is developing a multipurpose technology:
a three-month dapivirine-contraceptive ring designed to
offer both HIV prevention and contraception. Encouraging results from two Phase I trials supported the product’s
continued development, with the next Phase I trial planned
for 2022.

From Promise to Product
As women have remained the face of HIV, IPM is dedicated
to its vision by pioneering critically needed microbicide
research and development to help fill a gap for
woman-controlled HIV prevention options.
IPM extends its deepest thanks to our partners around the
world and to our generous donors, all of whom amplify our
efforts to improve women’s health. Realizing the lifesaving
potential of new products for women may be within our
reach. But only by continuing to unite scientific discovery
with political will and financial commitment, can we meet
women’s urgent sexual and reproductive health needs
globally.
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